A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel

Inclusion Criteria:

Subjects who present with Stage IV, Stage IIIB NSCLC or recurrent disease following radiation therapy or surgical resection
No prior chemotherapy or anti-EGFR targeted therapy
Sufficient tumor material for FISH testing
Measurable disease (RECIST)
ECOG performance status 0 or 1

Exclusion Criteria:

Symptomatic or uncontrolled CNS metastases
Inadequate hematologic function defined as ANC < 1,500/mm3, platelet count < 100,000/mm3, or a hemoglobin level < 9 g/dl
Inadequate hepatic function defined as total bilirubin > 1.25 x ULN, AST level > 1.5 x ULN, or alkaline phosphatase > 5.0 x ULN
Inadequate renal function defined by a serum creatinine level > 1.5 x ULN